Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.53 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.53 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.53 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.49 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.49 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.49 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1170552 | 1.00 | HTR2C (0.54) | HTR2CPDK1PDK2PDK3PDK4 | |
| SCHEMBL754805 | 1.00 | HTR2C (0.54) | HTR2CPDK1PDK2PDK3PDK4 | |
| SCHEMBL16903406 | 0.92 | HTR2C (0.52) | HTR2CPDK1PDK2PDK3PDK4 | |
| SCHEMBL24837430 | 0.90 | HTR2C (0.52) | HTR2CPDK1PDK2PDK3PDK4 | |
| SCHEMBL29182060 | 0.90 | HTR2C (0.52) | HTR2CPDK1PDK2PDK3PDK4 | |
| SCHEMBL30118103 | 0.90 | HTR2C (0.52) | HTR2CPDK1PDK2PDK3PDK4 | |
| SCHEMBL14209521 | 0.86 | HTR2C (0.57) | HTR2CPDK1PDK2PDK3PDK4 | |
| SCHEMBL31114244 | 0.86 | HTR2C (0.57) | HTR2CPDK1PDK2PDK3PDK4 | |
| SCHEMBL21751143 | 0.86 | PARP1 (0.47) | HTR2CPARP1PSEN1PSEN2APH1B | |
| SCHEMBL21326064 | 0.86 | PARP1 (0.47) | HTR2CPARP1PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747253-A1 | SPIROCYCLIC WRN HELICASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260115174-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT INC (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2025014846-A1 | SPIROCYCLIC WRN HELICASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115174-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | PDE6D, PDE6H, ADRA1D | HTR2C 544/4885PDK1 4522/4885PDK2 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.